

If Light Could Help: The Use of Transcranial Photobiomodulation in Parkinson's Disease. A Controlled Clinical Study.

Federica Peci¹, Rosjana Pica² and Samorindo Peci³

¹*Cerebro Company, Neuroscientific Research Unit, Milan, Italy*

²*San Celestino Institute, Rehabilitation Polyclinic, Milan, Italy*

³*Scientific Research Center (Ce.Ri.Fo.S), Milan, Italy*

*Correspondence to:

Federica Peci
Cerebro Company, Neuroscientific Research Unit,
Milan, Italy.

E-mail: federicapeci@cerebrostartup.it

Received: October 11, 2022

Accepted: March 13, 2023

Published: March 16, 2023

Citation: Peci F, Pica R, Peci S. 2023. If Light Could Help: The Use of Transcranial Photobiomodulation in Parkinson's Disease. A Controlled Clinical Study. *J Neurol Exp Neurosci* 9(1): 30-38.

Copyright: © 2023 Peci et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY) (<http://creativecommons.org/licenses/by/4.0>) which permits commercial use, including reproduction, adaptation, and distribution of the article provided the original author and source are credited.

Published by United Scientific Group

Abstract

Objective: The aim of this study is to investigate whether a 4-week physiotherapeutic rehabilitation combined with transcranial photobiomodulation (tPBM) treatment is more effective than the only motor rehabilitation and if the improvement persists at 1-month follow-up.

Methods: We investigated 40 Parkinson's disease (PD) patients, divided into two different groups: a control group that underwent only physiotherapeutic rehabilitation and the experimental one that underwent physiotherapeutic rehabilitation combined with PBM treatment. Outcome measures were UPDRS Part I, Part II and Part III. Patients were evaluated at admission, at the end of 4-week treatment and at 1 month follow up.

Results: All outcome measures improved for each group, but significantly improved at the end of treatment for the experimental group not only related to motor symptoms but also to everyday struggle.

Conclusion: Our results demonstrate that the combination of PBM treatment with physiotherapeutic rehabilitation was effective in improving motor symptoms in PD patients and the improvement in balance, gait and tremor were partially maintained after 1 month.

Keywords

Parkinson's disease, Photobiomodulation, Rehabilitation, Physiotherapy

Introduction

Overview of Parkinson's disease

Nowadays, one of the most widespread neurodegenerative disease is PD, with one case for every 50 people over 80 who are diagnosed with this pathology. The number of PD patients is constantly growing bringing the scientific community to assume that by 2040 this number will hit 12 million [1].

Main feature of PD is the dysregulation of neural circuits in basal ganglia, which are responsible for movement control. Moreover, a selective degeneration of dopaminergic neurons located in Substantia Nigra Pars Compacta is prominent and determines the weakens of muscular tone, gait, and limb movement due to the effect on the basal ganglia motor loop.

PD patients end up in a hypo-dopaminergic states that promotes, at a clinical level, limb rigidity, a generalized slow movement (bradykinesia), and a typical proximal tremor (from 4 - 6 Hz) of the upper extremity that progressively ex-

pands to the contralateral side.

Histologically, damaged neurons show an overproduction of intra-plasmatic inclusions that contain misfolded alpha-synuclein protein fibrils. These fibrils are known as Lewy Body and are a PD hallmark [2].

Although the exact cause of PD remains unknown, several studies show that PD is associated with genetic mutation, neurotoxicity, and vascular dysfunctions that initiate neural death [3-5]. Moreover, mitochondrial dysfunction resulting from the aforementioned factors play a crucial role in PD pathogenesis.

The first clinical approach for PD patient is the prescription of a drug that increases dopamine levels providing a precursor, L-dopa that replaces dopamine unable to pass through blood-brain barrier. This treatment seems to be useful in managing motor symptoms in the initial phase of PD, but its effectiveness decreases with a long-term use, causing often side effects such as dyskinesia [6, 7].

Epidemiological data estimate that the annual cost of a PD patient wander around 5,800 - 10,300 USD. In fact, the natural course of this disease is progressively slow causing a constant need to rely on public facilities and caregivers. Because of this epidemiological data and PD occurrence, several research groups tried to find a new way to help patients and to slow down the arising of some of the motor/cognitive symptoms of PD by finding new technologies based on non-invasive brain stimulation. One of these new approaches, covered in this paper, is tPBM.

What is photobiomodulation (PBM)?

This term describes the use of Red and Near Infra-red (NIR) light to relieve inflammation and pain and tissue death. The neural tissues are exposed to Low Flow Light with wavelengths that range from 600 to 1100 nanometres (nm) depending in which therapeutic method is used [8]. Over 50 years ago, Endre Mester discovered this technique while he was working on hair growth and wound healing in mice [9]; since then, PBM started being accepted in clinical practice and physiotherapy thanks to the availability of Light Emitting Diodes (LEDs) known to be safer, lower cost and better compatible with everyday life than Lasers [8, 9].

Many preclinical studies have been conducted to evaluate safety and optimal treatment parameters of Brain PBM [10-12]. It has been shown the neuroprotective effect of NIR LEDs in a variety of neurological conditions such as ischemic stroke [13], PD [14], traumatic brain injury [15], Alzheimer's disease, and psychological disorders such as depression and anxiety [16].

PBM is described as beneficial since it targets organs without causing aversive effects [16, 17] and increases Cerebral Blood Flow improving the brain energy metabolism [17, 18]. PBM can promote neuronal protection and survival through the mediation of anti-apoptotic and pro-apoptotic mediators [19, 20], inflammatory signalling molecules [21, 22], and stimulating neurotrophic factors [12-23]. PBM is demonstrated to have beneficial effects at behavioural level such as antidepressant effects, cognitive enhancement, and sleep improvement [15, 24-27].

tant effects, cognitive enhancement, and sleep improvement [15, 24-27].

PBM involves the use of light in a non-invasive and non-thermal way. The light from the visible and NIR spectrum produces cellular reactions triggering neuroprotective responses, improvement in metabolism, neurogenesis, improvement in blood flow, and decrease in oxidative stress and inflammation [16, 28].

The excitation of the mitochondrial Cytochrome-C Oxidase (CCO) is crucial for the effect of PBM since it is a major photoacceptor in the red to NIR light spectrum [29]. When exposed to this type of light, CCO undergoes an increase in the availability of electrons for the reduction of molecular oxygen with an increase in the mitochondrial membrane potential, increasing levels of adenosine triphosphate (ATP), cyclic adenosine monophosphate, and reactive oxygen species which point out an improvement in mitochondrial functioning in cellular metabolism [16, 28-32].

It is established that CCO itself is not the only photoacceptor capable of triggering cellular processes after being light stimulated. A review by Freitas and Hamblin shows that there are no less than fourteen different transcription factors and signalling mediators activated by light exposure [28]. From the initial photon absorption to the last behavioural effect on neurological disorders, a variety of processes occur that can be beneficial for brain disorders. These processes can be divided into short-term stimulation (ATP, blood flow, lymphatic flow, cerebral oxygenations, less edema); neuroprotection (upregulation of anti-apoptotic proteins, less excitotoxicity, more antioxidant, less inflammation); neurotrophins, neurogenesis and synaptogenesis [16, 34].

tPBM in PD

In the attempt to overcome the limits in daily practice management of PD, PBM has been included as an innovative technology for the treatment of motor and cognitive symptoms, especially in early stage of PD.

Initially, through *in vitro* studies, it has been observed that PBM reduces cellular apoptosis and oxidative stress, increasing neuronal production of ATP [35-37]. Studies demonstrate that the application of PBM on human cells enhances mitochondrial dysfunction and reduces oxidative stress [38-40].

The idea of using PBM as a therapeutic approach in PD comes from the strong belief that this disease is caused by a bioenergetics damage; since PBM is specific for the improvement of cell energy production it is one of the most innovative approaches of the last decade for PD treatment.

In addition, neuroinflammation is underlying PD and PBM offers immunomodulatory effects both at local and systemic level [41].

Long-term administration of PBM showed an astrogliosis reduction (a consequence of neuroinflammation) and a reduction in immunogenic cytokine; this results, combined with the absence of side effects of its use [42, 43], lend this technology more attractive for the treatment of this pathology.

At the present day, tPBM is a treatment that produces

positive effects in different clinical conditions such as Traumatic Brain Injury, stroke, and depression since the target brain areas are at a cortical level. On the other hand, the brain structures involved in PD are localized at 80 - 100 nm deep from the cranial suture and underneath the dura mater. Several studies show that the NIR light does not penetrate more than 20 mm deep from the cortex. This could surely be a limit to this technology applied to PD, if we consider PD as an involvement of only subcortical regions. Starting from a study conducted by Maloney et al., on PD patients showing that there is improvement in cognitive and motor symptoms after treatment with tPBM and the maintenance of enhancements until 2-weeks follow up [44], our research group tried to figure out the reason why such a near infrared light treatment at a cortical level is worthy in PD treatment.

Hypothesis

Our research hypothesis is that 810 nm tPBM allows motor cortical neurons to reinforce their metabolic mechanism [17, 18] that is impaired due to the damage set out to the subcortical structures [45]. According to a clinical point of view, if we combine a tPBM treatment (that activates motor cortical areas) with a physiotherapeutic rehabilitation treatment (that activates sensory-motor cortical areas) this will cause a bottom-up and top-down integration of sensory-motor information resulting in an improvement of motor and cognitive aspects. Obviously, combined with this evidence of sensory-motor integration is the ability of NIR light to reduce oxidative stress [16, 28] and to modulate neurotransmitters production.

The aim of this study is to investigate whether a 4-week physiotherapeutic rehabilitation combined with tPBM treatment is more effective than the only motor rehabilitation and if the improvement persists at 1-month follow-up.

Materials and Methods

The study was conducted in Milan, Italy. All participants gave written informed consent prior to taking part and all protocols were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were followed for this trial and a CONSORT flowchart (Figure 1a). The study is an experimental study with a randomized controlled trial (Figure 1b).

Participants

Patients enrolled were 38 diagnosed with PD aged between 60 and 75. Patients were divided into two different groups: 26 in the control group (18 men and 8 women), who performed only physiotherapeutic rehabilitation, and 12 in the experimental group (7 men and 5 women), who underwent physiotherapeutic rehabilitation combined with the treatment of PBM. Patients were randomly allocated either in the control or in the experimental group.

Most patients were currently treated with Levodopa and continued their intake during this study.

Exclusion criteria

- Use of illegal substances and drugs.
- Associated psychotic and psychiatric disorder.
- Epilepsy or other seizure disorder.
- Magnetic Resonance positive to neoplasm.

Experimental device and procedure of PBM

The experimental device, used for the PBM treatment, is Cerebro® NIR Infrared [16]. This device uses 256 LED set in 4 arrays of 64 LEDs/array all matched to 810 nm (Table 1).

NIR Infrared is calibrated to act on two channels: Channel 1 acts on the motor, premotor and visual cortex, Channel 2 acts on the executive, sensory and linguistic brain areas. The intensity of the two channels was modifiable, so Channel 1 was used at 100% intensity and Channel 2 at 75% intensity. NIR treatment was administrated for 18 minutes twice a week for one month.

Test and questionnaire

Both the control and the experimental group underwent Mini Mental State Examination (MMSE) test to assess possible cognitive impairment at admission [46]. The MMSE investigates different cognitive domains: temporal and spatial orientation, repetition, attention and calculation skills, memory recall and language. The total score on the test was 30. No patients showed cognitive impairment (Table 2).

To assess the treatment outcome of Parkinson's signs, patients were evaluated through the questionnaire MDS-UPDRS Part I, Part II and Part III [47]. Part I and Part II are completed by patient and caregiver, while Part III is evaluated by the operator. For each part, the scores showed 5 ranges:

Table 1: Device technical data.

Led Number	256	Power	50 mw
Output Power	15 W	Total Power	15 W
Input Voltage	100 - 240 V	Optical Power	24 mw/cm²
Input Current	0.8 (0.8a)	Work Voltage	5V --- 6A
Wavelength	810 nm	Power Frequency	50 - 60 Hz

Table 2: Questionnaires and test used to evaluate patients: MMSE Score (as an inclusion/exclusion criteria) and MDS-UPDRS Parts and Score.

MMSE: ≥ 26	MDS-UPDRS SCORE
MDS-UPDRS	
Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL)	0 = Normal 1 = Slight
Part II: Motor Aspects of Experiences of Daily Living (M-EDL)	2= Mild 3= Moderate
Part III: Motor Examination	4= Severe




Figure 1: (a) CONSORT flow chart and (b) Study design.

no impairment, slight, mild, moderate, and severe impairment (Table 2). Patients in both groups started from a moderate impairment score.

Patients were evaluated at admission, at the end of the 4-weeks treatment and at 1-month follow-up.

Data analysis

Data is collected and statistically analyzed using Office Excel and Jamovi version 2.2.5.0 using tables and graphs according to the group and the period of analysis.

Results

We investigated 38 patients diagnosed with PD, divided into two different groups: a control group that underwent only physiotherapeutic rehabilitation and the experimental one that underwent physiotherapeutic rehabilitation combined with PBM treatment. Outcome measures were UPDRS Part I, Part II and Part III.

Patients were evaluated at admission (T1), at the end of 4-week treatment (T2) and at 1-month follow up (T3). All patients at admission showed the same level of impairment (moderate).

Data obtained in the analysis of MDS-UPDRS Part I, which evaluates the non-Motor Aspects of Experiences of Daily Living (nM-EDL), show a clear improvement in the experimental group already at the second analysis, carried out after 4 weeks of treatment (T2) (Figure 2).

The control group showed a “moderate” score of impairment, detected in the first time of evaluation (t1) and a “mild” score in the second analysis (t2); at 1-month follow-up (T3) patients returned to a “moderate” score. The experimental group had a different reaction to the treatments: they started from a “moderate” score of impairments and after 4-week combined treatments (T2) reduced the impairment level into a “slight” score. The experimental group maintained a part of improvement acquired during treatment and at 1-month follow-up (T3) impairment levels were in a “mild” range.

The same analysis was carried out with a focus on the Motor Aspects of Experiences of Daily Living (MDS-UPDRS Part II: M-EDL) and Motor Examination (MDS-UPDRS Part III).

In Part II of the MDS-UPDRS, both the experimental and the control groups started with a score of 3.4 points at admission (T1). After a 4-week treatment (t”), the control group had a minimal improvement, with an average score of 2.4. A significant improvement was found in the experimental group, with an average score of 1.3 (Figure 3). At 1-month follow-up (T3), the control group obtained an average score of 3.4, while the experimental group obtained an average score of 2.4, demonstrating the persistence of improvement in time. After a month, patients generally felt a decrease in tremor and an improvement in walking and balance.

Our research team has also achieved important results at the motor level (Figure 4). Patients who underwent




Figure 2: The analysis of MDS-UPDRS Part I shows a clear improvement in the experimental group at the second analysis (T2), carried out after 4 weeks of treatment. Patients in the control group showed a “moderate” score of impairment, detected in the first analysis (T1) and a “mild” score in the second analysis (T2); at 1-month follow-up (T3) patients returned to “moderate”. Patients in the experimental group had a different reaction to the treatments: they started to a “moderate” score of impairments and after 4-week combined treatments (T2) reduced the impairment levels into a “slight” score.




Figure 3: Part II of the MDS-UPDRS, both the experimental and the control groups started with a score of 3.4 points at admission (T1). After a 4-week treatment (T2), the control group had minimal improvement, with an average score of 2.4. A significant improvement was found in the experimental group, with an average score of 1.3. At 1-month follow-up (T3), the control group obtained an average score of 3.4, while the experimental group obtained an average score of 2.4, demonstrating the persistence of improvement in time. After a month, patients generally felt a decrease in tremor and an improvement in walking and balance.




Figure 4: Analysis of MDS-UPDRS Part III shows that the experimental group improved in motor abilities after 4-weeks treatment (T2) with PBM, compared to the control group. After the 1-month follow-up (T3) the progress was partially maintained in the experimental group, while the control group returned to a “moderate” impairment score.

physiotherapeutic rehabilitation combined with PBM treatment gained a better improvement in motor symptoms after 4-weeks treatment (T2) with PBM, compared to the control group. After the 1-month follow-up (T3) the progress was partially maintained in the experimental group, while the control group returned to a “moderate” impairment score.

To analyze motor behavior, in terms of motor signs and motor aspects related to daily life, we compared the results obtained with MDS-UPDRS Part I and Part III, with a focus on the tests at admission (T1) and at follow-up (T3).

The data shows that in the control group, which only performed physiotherapeutic rehabilitation, levels of motor impairment return to a “moderate” score, as in the first analysis (T1). On the other hand, in the experimental group improvements at the motor level persist even one month after the end of the treatments (T3) (Figure 5).

A better result was obtained in the aspects related to daily life. Comparing Part I and Part II in the control and the experimental group, we observed that, while impairment levels in the control group returned to a “moderate” score, the experimental group maintained a “mild” scoring average in both Part I and II (Figure 6).

Data show how effective PBM is not only at the end of treatment, but also the 1-month follow up value is overall better and with a better resistance to the decline of improvements. That confirms the long-term efficacy of this technology. The t-test between the MDS-UPDRS in T1, T2 and T3 of the two groups show a solid significant difference in the T1 and T2 scoring between the two groups. The experimental group shows in fact a lower score, meaning that the symptoms and the impact on everyday life are considerably better than the control groups. The t-test confirmed how significant the improvement of the experimental group is, enhancing our hypotheses (Figure 7).

This test can allow us to show that the baseline of the groups is similar, not reporting any kind of differences in the MDS score at the beginning of the different treatment.

The repeated measures ANOVA analysis showed that the differences between the two groups are significant. The Post-hoc tests comparing the MDS score for each group in T0, T1 and T2 up shown significant differences in terms of scoring at T1 and T2 where the experimental group has a relevant lower score meaning that the symptoms and the impact on everyday life are considerably better than the control groups. Post-hoc confirmed how significant the improvement of the experimental group is, enhancing our hypotheses (Figure 7).

In addition, from interviews with patients and caregivers, the experimental group reported greater balance, safer walking, and an upright position. Above all, patients in the experimental group felt less fatigue and drowsiness, reduced feeling of lack in taking the upright position and improved mood.

Conclusion

The aim of this study is to provide a new clinical approach for patients diagnosed with PD. Different innovative




Figure 5: MDS-UPDRS Part II and Part III. Compared to the control group, the experimental group has maintained motor improvements one month after (T3) the end of the treatment.




Figure 6: MDS-UPDRS Part I and Part II. Compared to the control group, the experimental group-maintained improvements one month after the end of the treatment (T3).

techniques have brought to light in the last decades trying to improve patient's quality of life. One of these is PBM and especially NIR light that has been proven to be effective on many aspects of neuronal metabolic processes. The idea of using PBM as a therapeutic approach in PD comes from the strong belief that this disease is caused by a bioenergetics damage; since PBM is specific for the improvement of cell energy production it is one of the most innovative approaches of the last decade for PD treatment. In addition, neuroinflammation is underlying PD and PBM offers immunomodulatory effects both at local and systemic level [41]. Long-term administration of PBM showed an astrogliosis reduction (a consequence of neuroinflammation) and a reduction in immunogenic cytokine; this results, combined with the absence of side effects of its use [42, 43], lend this technology more attractive for the treatment of this pathology. Maloney et al., [44] provided evidence of PBM being effective on PD symptoms although it is not a disease in which cortical brain areas are primary involved. Based on this evidence, our study focused on determining if a combined 4-week treatment of 810 nm tPBM and physiotherapeutic rehabilitation could improve motor symptoms and extend the acquired improvement to 1-month follow up. It is well known and scientifically shared that PD is characterized by a subcortical damage related to neurons in Substantia Nigra Pars Compact but it is also characterized by many other metabolic dysfunctions that determines neuroinflammation. PD is associated with impairments related to the entire motor domain (such as walking, standing, turning, in-




Figure 7: Repeated measures ANOVA between subject and post-hoc comparison and graph. The higher the MDS score is, the worse the Parkinson's signs are.

stability in taking upright position and distal tremor), but it is impossible to firmly assume that there is absolutely no control exerted by the cortical motor areas. If there is a control system coming from above, from the cortical areas, spreading their information top-down to the subcortical ones but, in between, there is a shutdown (whether it is metabolic, electric, chemical, etc.) the information will not be integrated. The same process will happen from a bottom-up point of view: the information, coming from the distal parts of the body, tracing back to the subcortical regions in order to modulate neurotransmitter production (for i.e., muscular tone in order to move the left arm and lift a bag), will not be fully integrated with the cortical motor area because of a shutdown in the exact middle of the information pathway. How is it possible to prevent cortical motor areas from losing their neuronal activity and function-

ality? A try needs to be addressed to tPBM since it enhances metabolic processes, reduces oxidative stress in cells and promotes neurotransmitters production. In this study, thanks to the PBM device used it was possible to address NIR light to different brain areas (sensory-motor, prefrontal, visual, and cognitive cortical brain areas); this could prove evidence for improvements in sleep quality and mood swings. According to the questionnaire used to evaluate the efficacy of this combined tPBM-physiotherapeutic treatment, this combination was more effective than the only and classic physiotherapeutic rehabilitation.

In fact, all outcome measures improved for each group but improved significantly at the end of treatment for the experimental group not only related to motor symptoms but also to

everyday struggle.

The experimental group perceived improvement at the motor level, especially tremor reduction, improvement of visuo-spatial orientation, erect posture, and safe walking.

All patients in the experimental group detected improved mood, less drowsiness, and fatigue and reduced feeling of lack in taking the upright position. All these effects also remained at 1-month follow-up.

Results obtained are therefore coherent with our hypothesis about the need to enhance cortical metabolism, especially in primary motor areas, in order to improve neural mitochondrial activity and reduction in inflammatory and oxidative stress derived processes.

Limitation of the Study

The limitation of this study is surely the small sample size. Due to the small sample of PD patients and the device features it was not possible to include a third group treated as a Placebo/Sham Group that could undergo the same rehabilitation program as the experimental one but without the administration of NIR light. Future studies on PD patients and PBM should consider this type of Study Design in order to avoid placebo derived symptom improvements and further control over the PBM efficacy. Moreover, it would be interesting to integrate this data with the evaluation of overall Cognitive Impairments during each assessment time (T1, T2, and T3) in order to assess whether there is an increase also in MMSE scoring.

Acknowledgements

We would like to thank Rehabilitative Polyclinic San Celestino Institute in Milan (Italy) and Rehabilitative Polyclinic "Giano" in Cesena (Italy) for the data collection and the support in completing this paper. Thank you also to Alessio Giordanetto, student in Digital Psychology at the Sigmund Freud University in Milan, for the help in implementing the statistical analysis and revision to this paper.

Conflict of Interest

Federica Peci declares that she is the CEO of the company, whose NIR Infrared helmet was used in this study.

References

- Dorsey E, Sherer T, Okun MS, Bloem BR. 2018. The emerging evidence of the Parkinson pandemic. *J Parkinsons Dis* 8(S1): S3-S8. <https://doi.org/10.3233/JPD-181474>
- Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, et al. 1997. α -synuclein in Lewy bodies. *Nature* 388(6645): 839-840. <https://doi.org/10.1038/42166>
- Blesa J, Phani S, Jackson-Lewis V, Przedborski S. 2012. Classic and new animal models of Parkinson's disease. *J Biomed Biotechnol* 2012: 845618. <https://doi.org/10.1155/2012/845618>
- Carvey PM, Hendey B, Monahan AJ. 2009. The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. *J Neurochem* 111(2): 291-314. <https://doi.org/10.1111/j.1471-4159.2009.06319.x>
- Corti O, Brice A. 2013. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease. *Curr Opin Neurobiol* 23(1): 100-108. <https://doi.org/10.1016/j.conb.2012.11.002>
- Bergman H, Deuschl G. 2002. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. *Mov Disord* 17(S3): S28-S40. <https://doi.org/10.1002/mds.10140>
- Poewe W, Mahlknecht P, Jankovic J. 2012. Emerging therapies for Parkinson's disease. *Curr Opin Neurol* 25(4): 448-459. <https://doi.org/10.1097/WCO.0b013e3283542fde>
- Heiskanen V, Hamblin MR. 2018. Photobiomodulation: lasers vs. light emitting diodes?. *Photochem Photobiol Sci* 17(8): 1003-1017. <https://doi.org/10.1039/c8pp90049c>
- Mester A, Mester A. 2017. The history of photobiomodulation: Endre Mester (1903-1984). *Photomed Laser Surg* 35(8): 393-394. <https://doi.org/10.1089/pho.2017.4332>
- Sharma SK, Kharkwal GB, Sajo M, Huang YY, De Taboada L, et al. 2011. Dose response effects of 810 nm laser light on mouse primary cortical neurons. *Lasers Surg Med* 43(8): 851-859. <https://doi.org/10.1002/lsm.21100>
- Ilic S, Leichter S, Streeter J, Oron A, DeTaboada L, et al. 2006. Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. *Photomed Laser Surg* 24(4): 458-466. <https://doi.org/10.1089/pho.2006.24.458>
- Huang YY, Chen ACH, Carroll JD, Hamblin MR. 2009. Biphasic dose response in low level light therapy. *Dose Response* 7(4): 358-383. <https://doi.org/10.2203/dose-response.09-027.Hamblin>
- Yip KK, Lo SCL, Leung MCP, So KF, Tang CY, et al. 2011. The effect of low-energy laser irradiation on apoptotic factors following experimentally induced transient cerebral ischemia. *Neuroscience* 190: 301-306. <https://doi.org/10.1016/j.neuroscience.2011.06.022>
- Oueslati A, Lovisa B, Perrin J, Wagnières G, van den Bergh H, et al. 2015. Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease. *PLoS One* 10(10): e0140880. <https://doi.org/10.1371/journal.pone.0140880>
- Ando T, Xuan W, Xu T, Dai T, Sharma SK, et al. 2011. Comparison of therapeutic effects between pulsed and continuous wave 810-nm wavelength laser irradiation for traumatic brain injury in mice. *PLoS One* 6(10): e26212. <https://doi.org/10.1371/journal.pone.0026212>
- Peci S, Giannelli G, Pica R, Salvo G, Ivic K, et al. 2020. A pilot study of photobiomodulation therapy using NIR: pre and post 810 nm stimulation in patients affected by neurological diseases. *EC Neurology* 12: 103-118.
- Santana-Blank L, Rodriguez-Santana E, Santana-Rodriguez KE, Reyes H. 2016. "Quantum leap" in photobiomodulation therapy ushers in a new generation of light-based treatments for cancer and other complex diseases: perspective and mini-review. *Photomed Laser Surg* 34(3): 93-101. <https://doi.org/10.1089/pho.2015.4015>
- Chen Y, De Taboada L, O'Connor M, Delapp S, Zivin JA. 2013. Thermal effects of transcranial near-infrared laser irradiation on rabbit cortex. *Neurosci Lett* 553: 99-103. <https://doi.org/10.1016/j.neulet.2013.07.049>
- Purushothuman S, Johnstone DM, Nandasena C, Mitrofanis J, Stone J. 2014. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex—evidence from two transgenic mouse models. *Alzheimers Res Ther* 6: 1-13. <https://doi.org/10.1186/alzrt232>
- Quirk BJ, Torbey M, Buchmann E, Verma S, Whelan HT. 2012. Near-infrared photobiomodulation in an animal model of traumatic brain injury: improvements at the behavioral and biochemical levels. *Photomed Laser Surg* 30(9): 523-529. <https://doi.org/10.1089/pho.2012.3261>

21. Liang HL, Whelan HT, Eells JT, Meng H, Buchmann E, et al. 2006. Photobiomodulation partially rescues visual cortical neurons from cyanide-induced apoptosis. *Neuroscience* 139(2): 639-649. <https://doi.org/10.1016/j.neuroscience.2005.12.047>
22. Lee HI, Park JH, Park MY, Kim NG, Park KJ, et al. 2016. Pre-conditioning with transcranial low-level light therapy reduces neuroinflammation and protects blood-brain barrier after focal cerebral ischemia in mice. *Restor Neurol Neurosci* 34(2): 201-214. <https://doi.org/10.3233/RNN-150559>
23. Moreira MS, Velasco IT, Ferreira LS, Ariga SKK, Barbeiro DF, et al. 2009. Effect of phototherapy with low intensity laser on local and systemic immunomodulation following focal brain damage in rat. *J Photobiomodul Photobiol* 9(7): 145-151. <https://doi.org/10.1016/j.jphotobiol.2009.09.002>
24. Yan X, Liu J, Zhang Z, Li W, Sun S, et al. 2017. Low-level laser irradiation modulates brain-derived neurotrophic factor mRNA transcription through calcium-dependent activation of the ERK/CREB pathway. *Lasers Med Sci* 32(1): 169-180. <https://doi.org/10.1007/s10103-016-2099-0>
25. Xuan W, Huang L, Hamblin MR. 2016. Repeated transcranial low-level laser therapy for traumatic brain injury in mice: biphasic dose response and long-term treatment outcome. *J Biophotonics* 9(11-12): 1263-1272. <https://doi.org/10.1002/jbio.201500336>
26. Xu Z, Guo X, Yang Y, Tucker D, Lu Y, et al. 2017. Low-level laser irradiation improves depression-like behaviors in mice. *Mol Neurobiol* 54: 4551-4559. <https://doi.org/10.1007/s12035-016-9983-2>
27. Naeser MA, Zafonte R, Kregel MH, Martin PI, Frazier J, et al. 2014. Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. *J Neurotrauma* 31(11): 1008-1017. <https://doi.org/10.1089/neu.2013.3244>
28. Lapchak PA. 2010. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. *Ann Med* 42(8): 576-586. <https://doi.org/10.3109/07853890.2010.532811>
29. Hamblin MR, Demidova TN. 2006. Mechanisms of low level light therapy. *Mechanism Low Light Ther* 6140: 614001. <https://doi.org/10.1117/12.646294>
30. Cooper CE, Cope M, Springett R, Amess PN, Penrice J, et al. 1999. Use of mitochondrial inhibitors to demonstrate that cytochrome oxidase near-infrared spectroscopy can measure mitochondrial dysfunction noninvasively in the brain. *J Cereb Blood Flow Metab* 19(1): 27-38. <https://doi.org/10.1097/00004647-199901000-00003>
31. Hamblin MR. 2019. Photobiomodulation for Alzheimer's disease: has the light dawned?. *Photonics* 6(3): 77. <https://doi.org/10.3390/photonics6030077>
32. Hamblin MR. 2017. Photobiomodulation of the brain: a new paradigm. *Mechanism Photobiomod Ther XII* 10048: 1004802. <https://doi.org/10.1117/12.2255856>
33. Lane N. 2006. Cell biology: power games. *Nature* 443(7114): 901-904. <https://doi.org/10.1038/443901a>
34. Hamblin MR. 2016. Shining light on the head: photobiomodulation for brain disorders. *BBA Clin* 6: 113-124. <https://doi.org/10.1016/j.bbcli.2016.09.002>
35. Liang HL, Whelan HT, Eells JT, Wong-Riley MT. 2008. Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. *Neuroscience* 153(4): 963-974. <https://doi.org/10.1016/j.neuroscience.2008.03.042>
36. Ying R, Liang HL, Whelan HT, Eells JT, Wong-Riley MT. 2008. Pre-treatment with near-infrared light via light-emitting diode provides added benefit against rotenone- and MPP+-induced neurotoxicity. *Brain Res* 1243: 167-173. <https://doi.org/10.1016/j.brainres.2008.09.057>
37. Vos M, Lovisa B, Geens A, Morais VA, Wagnieres G, et al. 2013. Near-infrared 808 nm light boosts complex IV-dependent respiration and rescues a Parkinson-related pink1 model. *PLoS One* 8(11): e78562. <https://doi.org/10.1371/journal.pone.0078562>
38. Quirk BJ, DeSmet KD, Henry M, Buchmann E, Wong-Riley M, et al. 2012. Therapeutic effect of near infrared (NIR) light on Parkinson's disease models. *Front Biosci* 4: 818-823. <https://doi.org/10.2741/E421>
39. Trimmer PA, Schwartz KM, Borland MK, De Taboada L, Streeter J, et al. 2009. Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. *Mol Neurodegener* 4: 1-11. <https://doi.org/10.1186/1750-1326-4-26>
40. Hong N. 2019. Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. *Biomed Eng Lett* 9(3): 359-366. <https://doi.org/10.1007/s13534-019-00115-x>
41. Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. 2016. Turning on lights to stop neurodegeneration: the potential of near infrared light therapy in Alzheimer's and Parkinson's disease. *Front Neurosci* 9: 500. <https://doi.org/10.3389/fnins.2015.00500>
42. Moro C, Torres N, Arvanitakis K, Cullen K, Chabrol C, et al. 2017. No evidence for toxicity after long-term photobiomodulation in normal non-human primates. *Exp Brain Res* 235: 3081-3092. <https://doi.org/10.1007/s00221-017-5048-7>
43. Hamilton CL, El Khoury H, Hamilton D, Nicklason F, Mitrofanis J. 2019. "Buckets": early observations on the use of red and infrared light helmets in Parkinson's disease patients. *Photobiomodul Photomed Laser Surg* 37(10): 615-622. <https://doi.org/10.1089/photob.2019.4663>
44. Maloney R, Shanks S, Maloney J. 2010. The application of low-level laser therapy for the symptomatic care of late stage Parkinson's disease: a non-controlled, non-randomized study. *Lasers Surgery Med* 185: 61.
45. Vos M, Lovisa B, Geens A, Morais VA, Wagnieres G, et al. 2013. Near-infrared 808 nm light boosts complex IV-dependent respiration and rescues a Parkinson-related pink1 model. *PLoS One* 8(11): e78562. <https://doi.org/10.1371/journal.pone.0078562>
46. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12(3): 189-198. [https://doi.org/10.1016/0022-3956\(75\)90026-6](https://doi.org/10.1016/0022-3956(75)90026-6)
47. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, et al. 2008. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 23(15): 2129-2170. <https://doi.org/10.1002/mds.22340>